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An estimated 10–20% of adults suffer from IBS, a func-
tional gastrointestinal disorder that negatively affects pa-
tient’s quality of life (QoL). As part of a one-year random-
ized, double blind, placebo-controlled study (S3B30006) of
the 5HT3 receptor antagonist alosetron in women with
IBS, QoL was assessed using the IBSQOL. OBJECTIVE:
To determine the smallest score change on each IBSQOL
scale that can be considered meaningful to the patient.
METHODS: The IBSQOL consists of nine scales, each
yielding a score of 0–100, with higher scores representing
better QoL. Subjects completed the IBSQOL at baseline
and both the IBSQOL and a global assessment question-
naire at months 1 and 2. The global assessment question-
naire contained nine items corresponding to the nine
scales of the IBSQOL. For each item, subjects rated the
change, if any, in a specific aspect of QoL relative to
baseline on a 7-point scale, ranging from “markedly
worse” to “markedly improved.” For each IBSQOL
scale, the average change score for subjects rating them-
selves as “slightly improved,” irrespective of treatment
group, was calculated to establish the minimum mean-
ingful difference (MMD). Average change scores for
“moderately improved” subjects were also calculated.
RESULTS: The MMDs were based on 90–127 subjects
per scale with the exception of sexual relations (n  46).
The following MMDs were determined: emotional—16.9
(SD  20.2); mental health—9.0 (18.7); sleep—11.6
(19.0); energy—18.6 (20.8); physical functioning—11.3
(19.0); food—12.5 (18.6); social functioning—14.5 (17.9);
role-physical—18.9 (19.1); sexual relations—19.4 (19.7).
Score changes corresponding to moderate improvements
were: emotional—24.8 (23.7); mental health—18.4
(18.6); sleep—18.4 (19.0); energy—30.4 (25.1); physical
functioning—20.8 (20.3); food—21.3 (19.4); social func-
tioning—27.2 (20.3); role-physical—27.4 (25.0); sexual
relations—26.1 (26.3). CONCLUSION: Determination
of MMDs for the IBSQOL may serve as a useful interpre-
tive tool.
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INCORPORATING MEASUREMENT OF INDIRECT 
COSTS IN THE EVALUATION OF AN ASTHMA 
HEALTH MANAGEMENT PROGRAM
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Evaluations of Integrated Therapeutics Group (ITG)
Asthma Health Management (AHM) programs have in-
cluded measures of clinical outcomes, utilization/medical
expenditures and QoL. To date, indirect costs have not
been systematically assessed. OBJECTIVES: As part of
an effort to develop and validate survey measures of pro-
ductivity, this study will present significant correlates of
baseline (pre-AHM implementation) mean annual costs
associated with missed days from work due to asthma.
METHODS: Data were obtained from self-reports from
a random sample of adult, employed asthmatics who
completed a mailed survey (N  1275) prior to participa-
tion in an AHM program. The dependent variable was
mean annual costs associated with missed days from
work due to asthma, derived by annualizing missed days
reported in the survey and multiplied by an estimate of
wages. Independent variables included sociodemograph-
ics, health status measures, asthma-related symptomatol-
ogy, utilization of medical services/pharmaceuticals, atti-
tudes and beliefs. RESULTS: Mean annual indirect costs
were $647 (95% CI $541–$754). In order of entrance
into a multiple regression equation, significant predictors
(P  0.05) of increased costs were: 1) asthma-related ER/
inpatient episode; 2) rating of health status as fair/poor;
3) low self-confidence in ability to manage asthma); 4)
adverse symptomatology profile; (5) comorbidity of res-
piratory allergies; and 6) daily use of bronchodilators. As
obtained from the multivariate model, an ER/inpatient
episode generated an increase of $998 associated with
missed work days, and relative to their more confident
counterparts, patients with less confidence had increased
expenditures of $344. CONCLUSIONS: Consistent with
national data, this study reveals a substantial indirect
cost burden associated with asthma. One year follow-up
data on the impact of the ITG AHM program on these
indirect costs will be presented.
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OBJECTIVE: This paper investigates the extent to which
absenteeism among newly diagnosed, employed patients
with depression varied among those who initiated treat-
ment with a TCA or SSRI. Subjects were drawn from the
MEDSTAT® Group’s MarketScan® and Illumina® Da-
tabases. METHODS: These databases include informa-
tion on the health care use of workers of large employers
in the US. The final analytical sample contained 716
newly diagnosed employees between 1994–1996 who
had absenteeism data available. Patterns of absenteeism
over the six-months prior to and twelve-months follow-
ing the initiation of pharmacotherapy were examined. In
addition, the number of absences during the twelve-
month follow-up period was analyzed using a multivari-
ate regression method specifically designed for non-nega-
tive dependent variables. RESULTS: Mean monthly ab-
sences equaled 4.7 at six-months prior to drug treatment
and rose to 10.2 during the month of initial antidepres-
sant treatment. Six-months after antidepressant treat-
ment commenced, absences declined approximately 40%
to 6 per month. The mean number of total absences dur-
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ing the year follow-up were significantly higher for pa-
tients beginning treatment with a TCA than with a SSRI,
101.7 (SD 68.9) versus 81.6 (SD 63.5). Controlling for
confounders, males had fewer absences than females. La-
bor union members had significantly more absences than
did non-union workers. Initiating treatment with a TCA
resulted in nine additional absences compared to those
beginning treatment with a SSRI. CONCLUSIONS:
Treatment of depression with antidepressants appears to
lead to improved work outcomes through decreased ab-
senteeism. Initiating treatment with a SSRI as opposed to
a TCA may reduce the indirect costs of this disease in
terms of time away from work.
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Pharmacists have been working to help patients better
manage their health through disease state management
(DSM) programs. Because third party payers have been
reluctant to provide reimbursement for these services,
pharmacists are starting to bill the patient for payment. A
better understanding of who to target and how much to
charge for DSM programs would be beneficial to phar-
macists in developing and providing these programs. OB-
JECTIVE: The purpose of this study was to determine
what factors influence patient willingness to pay (WTP)
for a diabetes DSM program. METHODS: One hundred
fifty-five adult patients with diabetes were surveyed by
mail on the following factors to determine their effect on
WTP for a diabetes DSM program: patient satisfaction
with pharmacy services, health care utilization (hospital-
izations and emergency room visits), perceived need for
DSM, and sociodemographic factors. RESULTS: Patients
were willing to pay on average $27.80 (SD  $31.80) for
a one hour diabetes DSM consultation with the pharma-
cist. A regression model revealed that several factors sig-
nificantly (P  0.05) influenced patient WTP. Patients
who were likely to pay more for a diabetes DSM had a
greater perceived need for the service (P  0.004), had
more emergency room visits (P  0.0001), were more
likely to be male (P  0.009), were more likely to be
older (P  0.046), and had higher incomes (P  0.001)
This model was significant (P  0.0001) with 32 percent
of the variance explained. Although patient satisfaction
was not significant, it was positively correlated with
WTP. CONCLUSIONS: The project results may be use-
ful to pharmacists when determining the level of payment
for services, as well as targeting specific individuals and
tailoring DSM programs to meet diabetic patients’ needs.
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OBJECTIVE: The twofold purpose of the study was to:
1) develop health state descriptions of diabetic peripheral
neuropathy (DPN) and its complications for a new utility
instrument, and 2) use these descriptions to assess patient
preferences for health states associated with disease pro-
gression in DPN. METHODS: Development and pilot
testing of seven standardized health state scenarios de-
scribing disease progression and complications in DPN
have previously been presented. These seven states are
mild neuropathy, painful neuropathy, severe neuropathy,
mild ulcer, severe ulcer, minor amputation (toe) and ma-
jor amputation (below the knee). Patients between the
ages of 18 and 80 years were recruited from registries of
diabetic patients at the University of Washington Medi-
cal Center and the Seattle VA. Patients with a history of
DPN symptoms or complications were excluded. Each
patient completed a computer interview using the U-Titer
II utility measurement software. Both a rating scale (RS)
and a standard gamble (SG) technique were used to
quantify patient preferences for standardized descriptions
of the seven health states. RESULTS: 52 patients com-
pleted the 60-minute exercise. Overall, the mean utilities
for the seven health states were lower with the RS (0.86
to 0.27) when compared to the SG (0.87 to 0.61). The
preference scores followed a logical, decreasing order, in
accordance with severity, with the exception of the utility
for minor amputation being higher than for severe ulcer.
Neither previous knowledge of DPN nor demographic
characteristics were significant predictors of utility. CON-
CLUSIONS: This study has reported on the development
and evaluation of a new preference-based instrument for
use in DPN.
Cost Analyses CAN
CAN1
COMPARISON OF COSTS OF ASTHMA 
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Traditionally, bronchodilation with theophylline has
been a mainstay of treatment for persistent asthma. Cur-
rent treatment guidelines, however, call for reliance on
anti-inflammatory therapy and recommend that theo-
phylline and other long-acting bronchodilators be re-
